Gaur S, et al. - Using the LNCaP, C4-2B, and 22Rv1 human prostate cancer cell lines, researchers analyzed the potential role of monoamine oxidase A (MAOA) inhibitors (MAOAIs) in the androgen receptor (AR) pathway and resistance to antiandrogen therapy in prostate cancer cases. They noticed a decline in MAOA activity in human prostate cancer cells with use of MAOAIs, especially clorgyline and phenelzine. A decrease in growth of LNCaP, C4-2B, and 22Rv1 cells was observed with MAOAIs use. They noted production of additive growth inhibitory effects when MAOAIs were combined with enzalutamide. Either alone or in combination with antiandrogens, MAOA inhibitors were supported by the data for therapeutic intent in patients with advanced forms of prostate cancer.